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IntrOductIOn
Mucopolysaccaridoses (MPS) are rare metabolic disorders that 
are inherited in an autosomal recessive pattern, and demonstrate 
cardiovascular involvement [1]. Depending on the type of enzyme 
deficiency, the catabolism of Dermatan Sulfate (DS), Heparan 
Sulfate (HS), Keratin Sulfate (KS), chondroitin sulfate or hyaluronan 
may be blocked. Lysosomal accumulation of GAGs molecules 
results in cells, tissues and organ dysfunction, including the heart 
[2,3]. Children with MPS display clinical symptoms that include 
skeletal abnormalities, CNS deterioration, cardiac dysfunction, 
corneal clouding, loss of hearing, enlarged abdominal organs, and 
obstructive airway disease [4]. All MPS types have an autosomal 
recessive inheritance except type II, which has an X linked 
inheritance. Despite the biochemical and genetic heterogeneity, 
different MPS types have similar clinical presentation [5]. Urinary 
Glycosaminoglycans (GAGs) levels and enzyme activity assays are 
required to confirm variable MPS types. Measurement of enzyme 
activities in leukocytes or cultured fibroblasts is currently the gold 
standard for diagnosing a specific MPS type(s) [6,7]. The skeletal 
abnormalities are collectively referred to as dysostosis multiplex. 
The characteristic radiographic findings include paddle-shaped 
ribs, thick clavicles, odontoid hypoplasia, platyspondyly, wedge-
shaped vertebral bodies with anterior breaking, dorsal kyphosis, 
lumbar gibbus, wide disc spaces and, spinal canal stenosis. These 
skeletal changes result in restricted mobility, arrest of growth in 
childhood and, short stature [8].
Deposition of GAGs in the heart leads to cardiomyopathy or cardiac 
valve disease [9,10]. Nevertheless, development of coronary 
artery disease and sub-clinical atherosclerosis in children with 
severe Mucopolysaccharidosis(MRS) type I and cardiomyopathy 
has been reported [11,12]. Cardiorespiratory disease tends to 
progress with age and is the most common cause of death. With 
 
the development of Enzyme Replacement Therapy (ERT) for many 
of these disorders, the results of therapies will rely heavily upon 
early detection and treatment, before irreversible damages. Long-
term ERT is beneficial for the myocardium, but the cardiac valves 
involvement appears irrevesible [13,14].
The present study was conducted, to evaluate the cardiac 
involvement in Egyptian children with MPS.
MAterIAls And MethOds
This was a cross-sectional study of 34 pediatric patients with 
MPS who attended the neurometabolic clinic at Cairo University 
Children Hospital, from January 2013 to June 2014. The study 
was approved by the Institutional Ethics Committee. The study 
was performed according to the principles of the Declaration 
of Helsinki (2008). Informed consent was obtained from all the 
parents. The mean age ±standard deviation of the participants 
was 5.7 ± 3.77 years and number of male patients was 23. The 
measurement of enzyme activities was done to confirm different 
types of MPS. Enzymatic assays were carried out according to the 
methods described by Kresse et al., [15].
All patients were subjected to thorough medical history 
assessments that included family history and a three-generation 
pedigree analysis of parental consanguinity and any similarly 
affected family members. Full clinical examination was done to 
detect features of MPS disorders. 
Skeletal survey was conducted for all cases to detect evidence 
of skeletal abnormalities [Table/Fig-1a,b]. Quantitative and 
electrophoretic analysis of urinary (GAGs) as well as enzymatic 
analysis for types of MPS was done to measure the activities of α-L-
iduronidase, iduronate-2-sulfatase, α-N-acetylglucosaminidase, 
galactosamine-6-sulfatase, arylsulfatase B in the White Blood 
Cells [Table/Fig-2].
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Introduction: The Mucopolysaccharidoses (MPS) are rare 
inherited metabolic disorders. They are characterized by the 
progressive systemic deposition of glycosaminoglycans (GAGs). 
GAGs accumulate in the myocardium and the cardiac valves. 
Enzyme Replacement Therapy (ERT) is available for MPS I, II, 
and VI. However, ERT does not appear to improve cardiac valve 
disease for patients with valve disease present at the start of 
ERT. 
Aim: To evaluate the cardiac involvement in Egyptian children 
with MPS.
Materials and Methods: Echocardiograms (ECG) were 
done for 34 patients. Both quantitative and qualitative 
Glycosaminoglycans (GAGs) in urine and enzyme assay 
confirmed the diagnosis. Mitral, tricuspid and aortic valves were 
evaluated for increased thickness, regurgitation and/or stenosis, 
left ventricular chamber dimensions, septal and posterior wall 
thicknesses.
results: The patients’ age ranged from 0.9-16-year-old (median 
age 4 years). They included 19 cases of MPS I (55.9%), 3 cases 
of MPS II (8.8%), 2 cases of MPS III (5.9%), 6 cases of MPS 
IV (17.6%) and 4 cases of MPS VI (11.8%). Heart murmur was 
heard in 9 of the participants (9/34) (26%). However, 15 patients 
(15/34) (44%) revealed cardiac lesions on ECG examinations. 
Mitral regurge (47%), followed by pulmonary hypertension 
(40%), were the most frequent findings. 
conclusion: The absence of Cardiac murmurs does not 
exclude the heart involvement. Cardiac valve dysfunction may 
not be reversible. Regular ECG should be routinely warranted in 
children with MPS and early ERT are recommended.
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Electrocardiogram (ECG) was performed for all cases in the supine, 
left lateral position using General Electric (GE, Vivid-5) system with 
probe 3 or 5 MHz (multi-frequency transducer) according to the 
age of patient, having tissue velocity imaging capabilities. The 
electrocardiography was connected to time the cardiac cycle 
events. The examination consisted of M-mode, two-dimensional, 
pulsed-wave and colour Doppler blood flow velocity assessments 
of the cardiac valves. 
Other investigations, such as Magnetic Resonance Imaging (MRI) 
of brain and spine was done, Auditory brain stem evoked potential 
was obtained from those MPS patients with hearing problems 
(otitis media) and median nerve conduction velocity was done to 
diagnose cases of carpal tunnel syndrome. 
stAtIstIcAl AnAlysIs 
Statistical Package for Social Science (SPSS) program version 17 
was used for data analysis. Data was described in terms of mean 
± standard deviation (±SD), or frequencies (number of cases) and 
percentages when appropriate. 
results
The study was conducted on 34 patients, aged 9 months –16-
year-old; the mean age (±standard deviation) of the participants 
was 5.7 ± 3.77 years, with 23 male and 11 female. There were 
19 cases of MPS (55.9%), 3 cases of MPS II (8.8%), 2 cases of 
MPS III (5.9%), 6 cases of MPS IV (17.6%) and 4 cases of MPS VI 
(11.8%). A total of 13 (38%) patients have positive family history of 
similar condition. Coarse facial features were present in all cases 
of Hunter and Sanfilippo Syndrome and were the most common 
finding in Hurler cases (70%). Corneal clouding was seen in 
Hurler and Hunter patients while absent in Sanfilippo, Morquio 
and Maroteaux-Lamy patients. Heart Murmur was heard in nine 
(9/34) cases (26%), with higher prevalence in Maroteaux-Lamy 
patients (50%). Hyperactivity was apparent in Sanfilippo cases. 
Median nerve conduction velocity showed Bilateral median nerve 
neuropathy of axonal nature, in 6 patients (17.6%). It ranges 
between moderate to severe degrees. The findings of clinical 
characteristics were represented in [Table/Fig-3].
ECG was performed in all patients. Cardiac abnormalities were 
detected in 15 patients (44%) such as mitral valve lesions, 
pulmonary hypertension, concentric left ventricle hypertrophy/
dilatation, tricuspid regurge and/or aortic regurge. Mitral regurge 
(47%) followed by pulmonary hypertension (40%) were the 
most common findings among MPS patients [Table/Fig-4]. We 
encountered 3 patients with MPS I in whom the predominating 
heart problems were infiltration of the valvular cusps, ventricular 
hypertrophy and/or dilatation leading to mitral valve insufficiency 
and pulmonary hypertension. Cardiac lesions in various types 
of MPS are shown in [Table/Fig-5]. ECG showed ST segment 
depression-abnormality and negative T-wave, in cases of 
concentric Left ventricle hypertrophy.
One patient with Hunter disease died at age 10 years. His echo 
showed mitral regurge and dilated left ventricle. His death was 
thought to be related to the cardiac abnormalities.
MRI of brain and spine, were available in 31 cases [Table/Fig-6]. 
Out of 31, 24 cases (77%) have abnormal findings. Demyelination, 
incomplete myelination and dysmyelination are described in 11/31 
patients (35%). Abnormal dorsolumbar vertebra was described in 
2(6%) cases, while four patients (13%) had Venticulomegaly; one 
of whom had ventriculoperitoneal shunt operation.
[table/Fig-1]: (a) Skeletal survey of a five-year-old girl with type VI. Enlarged 
cranium-J shaped sella turcica-enlarged heart-wide ribs-dorsolumber gibbus at D12/
L1-anterior breaking of vertebral bodies.
(b) The same patient’s hand- wide metacarpal, proximal and middle phalanges-
pointed proximal ends of the second to fifth phalanges.
MPS i hurler
(N = 19)
MPS ii 
hunter
(N = 3)
MPS iii 
Sanfilippo
(N = 2)
MPS iV 
Morquio
(N = 6)
MPS Vi 
Maroteax-
Lamy
(N = 4)
Dysostosis 
multiplex
18(95%) 3(100%) 2(100%) 6(100%) 3(75%)
GAG in 
Urine
DS,HS DS,HS HS KS DS
Enzyme 
assay
alpha – 
L-iduronidase
iduronate 2 
sulphatase
Alpha-N-
acetylglucos-
aminidase
N acetyl 
galactosamine-
6-sulfatase
aryl-
sulphatase
[table/Fig-2]: Investigations to confirm different types of MPS.
GAG: glycosaminglycan, DS;Dermatan sulphate, HS;Heparan sulphate, KS;Keratan sulphate.
hurler
(N = 19)
hunter
(N =3 )
Sanfilippo 
(N = 2)
Morquio
(N = 6)
Maroteaux- 
Lamy
(N = 4)
Coarse facial 
features
19(100%) 3(100%) 2(100%) 4(66.6%) 4(100%)
Macrocephaly 13(68%) 1(33%) 2(100%) 4(66.6%) -
Corneal clouding 10(53%) 1(33%) - - 3(75%)
Chronic nasal 
congestion / 
snoring/Adenoids
3(16%) 2(66%) - - 3(75%)
Heart murmur 4(21%) 1(33%) - 1(16.6%) 2(50%)
inguinal and/or 
umbilical hernia
10(53%) 2(66%) - 1(16.6%) 1(25%)
liver and spleen 
enlargement
5(26%) 2(66%) 1(50%) - 2(50%)
Short stature 10(53%) 2(66%) 1(50%) 3(50%) 2(50%)
Kyphosis 2(10.5%) 1(33%) - 2(33%) -
Genu valgus - - - 2(33%) -
Hearing loss 1(5%) - - 1(16.6%) -
Hyperactivity - - 2(100%) - -
Carpal tunnel 
syndrome
2(10.5%) 2(66%) - 2(33%)
[table/Fig-3]: Frequency of the clinical findings of individuals with MPS.
[table/Fig-4]: Echocardiographic findings in MPS Patients.
TR; Tricuspid Regurge, MR; Mitral Regurge, AR; Aortic regurge
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dIscussIOn
Cardiac abnormalities have been observed in patients with MPS 
of any types. However, an early diagnosis is difficult due to joint 
stiffness, respiratory system involvement or skeletal malformations 
that limit exercise capacity and mask the underlining heart failure 
[16]. The most frequent MPS type in Egyptian children was type 
I (56%). The anatomical changes of cardiovascular systems were 
common in all types of MPS patients. In another study, among 
Taiwanese children, the most common type was type II (43%) [17]. 
In this study, the heart murmur was heard in 26% of our patients 
with MPS. Mitral regurgitation was the most common echo finding. 
Rigante and Signi found clinical evidence in most cases that have 
moderate-to-severe somatic disease [9]. Thickening of the valve 
leaflets, commonly leads to mitral and aortic regurgitation rather 
than stenosis [3].
It has been suggested that, cardiomyopathy and valve defects 
occur as GAGs accumulate in the myocardium, spongiosa 
of cardiac valves, and myointima of coronary arteries [5]. 
Histologically, cytoplasmic vacuolation may be observed in cells 
of mitral valves, in coronary arteries and in the aorta; electron-
microscopically, the same cardiomyocytes may appear enlarged 
or packed with electron-lucent cytoplasmic vacuoles, which are 
stored undegraded GAGs [17]. The deformed valves showed 
mitral or aortic leaflets thickening and calcification, and may 
lead to various severities of stenosis or regurgitation. Pulmonary 
hypertension is the second echo finding in our patients. There 
was a strong association between the accumulation of dermatan 
sulphate and the presence of valvular dysfunction, and pulmonary 
hypertension [18]. Rheumatic mitral valve was diagnosed in one 
patient however, these findings could be attributed to infiltration 
of polysaccharides or mucosubstances instead of rheumatic 
involvement [10]. Moreover, multi-system disease involving the 
dermatological, musculoskeletal, cardiac and gastrointestinal 
system could suggest storage disease [19]. Cardiovascular 
abnormalities among patients with MPS III were rare and less 
severe than among other groups [20]. Similar to our study, one of 
those has mild tricuspid regurge.
Valvular deformation and thickening, thick interventricular septum 
and diastolic dysfunction were found to worsen with age [17]. 
Insofar, ECG and Echo should be done regularly during follow-up 
of MPS patients [21]. Valvular lesions causing valvular stenosis or 
insufficiency are an indication for infectious endocarditis prophylaxis 
before surgical and dental treatment [22]. Valvular disease, 
myocardial thickening, systemic and pulmonary hypertension [18] 
or narrowing of the coronary arteries with ischemia, all contribute 
to instances of sudden cardiovascular collapse [9]. 
Treatment options for MPS include, either haematopoietic stem 
cell transplantation, which is useful for selected patients or 
recombinant I.V enzyme replacement therapy. ERT is available 
for MPS I, II, VI [6], and recently for type IV [23]. ERT may alter 
the course of ventricular hypertrophy but cardiac valve pathology 
is usually unresponsive or, at best, stabilized [24]. In Taiwanese 
study of patients with MPS VI, ERT reduced urinary GAG and had 
positive effects on cardiac hypertrophy and diastolic dysfunction 
[25]. Early ERT may prevent valve disease, a fact that emphasizes 
the importance of early diagnosis and treatment in MPS [3].
cOnclusIOn
Echocardiography is a key diagnostic technique for evaluation 
of valves, ventricular dimensions and function; even among 
asymptomatic patients. Serial ECG in patients with MPS are 
recommended to assess ventricular function and the progression 
of cardiac abnormalities. Prompt diagnosis and treatment are 
mandatory before irreversible damage.
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